Piper Jaffray Initiates Coverage Of Cronos, Says Stock 'Warrants A Premium Valuation'

0
44
This post was originally published on this site

Read more about our latest Cannabis News! CANNABIS HOME

Cannabis stocks got a boost on Tuesday after a major Wall Street firm initiated bullish coverage of Cronos Group Inc (NASDAQ: CRON).

The Analyst

Piper Jaffray analyst Michael Lavery initiated coverage of Cronos with an Overweight rating and $18 price target.

The Thesis

Lavery said Cronos is well positioned for years of strong top-line growth as the cannabis industry expands over time. He also said the partnership with Altria Group Inc (NYSE: MO) has tremendous advantages from Cronos. In addition to providing access to 230,000 U.S. retail locations, Altria has much-needed legal and regulatory expertise.

“We expect Cronos to have modest near-term revenues from Canadian cannabis production, but believe it has significant potential growth opportunities with CBD products in the US, including through its pending acquisition of the Lord Jones brand,” Lavery wrote in a note.

Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.

Lavery said Cronos will likely utilize its $1.8 billion in capital from the Altria deal to launch a U.S. CBD business within the next year, potentially targeting vapes and topicals. He is projecting CBD will account for 60% of Cronos revenue in 2020.

Today, Piper Jaffray estimates the global legal cannabis market is valued at between $15 billion and $50 billion, but Lavery said that value could grow to between $250 billion and $500 billion over time. Medicinal cannabis should gain share from prescription pain killers, sleep aids and other drugs.

While Cronos shares are richly valued, Lavery said its growth potential and access to capital and U.S. retail warrant a premium valuation.

Price Action

Cronos shares traded higher by 4% to $13.75 at time of publication. Lavery also initiated coverage on other cannabis stocks:

  • Aurora Cannabis (NYSE: ACB) with a Neutral rating, $7 price target
  • Cresco Labs (OTC: CRLBF) with a Overweight rating, $11 price target
  • CV Sciences (OTC: CVSI) with a Overweight rating, $5 price target

Latest Ratings for CRON

Date Firm Action From To
Aug 2019 Initiates Coverage On Overweight
Aug 2019 Reiterates Buy
Aug 2019 Upgrades Sell Hold

View More Analyst Ratings for CRON
View the Latest Analyst Ratings

Read more about our latest Cannabis News! CANNABIS HOME

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.